Search Within

Sergio Andres Giralt

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (143)
  2. Journal Article (75)
  3. Research Letter (4)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (223)
  2. Center for Hematologic Malignancies (223)
  3. Department of Medicine (223)
  4. Hematologic Malignancies, Division of (223)
  5. Sloan Kettering Institute Postdocs (223)
  6. Survivorship Research (195)

More Groups

People
  1. Gunjan Shah (142)
  2. Michael Scordo (141)
  3. Alexander Lesokhin (121)
  4. Heather Landau (120)
  5. Sham Mailankody (120)
  6. Malin Hultcrantz (119)

More People

Years
  1. 2025 (6)
  2. 2024 (35)
  3. 2023 (52)
  4. 2022 (34)
  5. 2021 (20)
  6. 2020 (18)

More Years

Publications
  1. Blood (84)
  2. Clinical Lymphoma, Myeloma and Leukemia (36)
  3. Biology of Blood and Marrow Transplantation (25)
  4. Journal of Clinical Oncology (11)
  5. Blood Advances (8)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (92)
  2. Elsevier Inc. (68)
  3. Nature Publishing Group (13)
  4. American Society of Clinical Oncology (11)
  5. Oxford University Press (5)
  6. American Association for the Advancement of Science (4)

More Publishers

Results (223)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)
    Meeting Abstract

    Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save